News | Radiation Therapy | July 20, 2021

ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images


July 20, 2021 — In response to consecutive weeks of proposed Medicare payment cuts to radiation oncology cancer care, Thomas J. Eichler, M.D., FASTRO, Chair of American Society for Radiation Oncology (ASTRO), issued the following statement:

“Access to radiation therapy for people with cancer is under attack. For two consecutive weeks, the Centers for Medicare and Medicaid Services (CMS) has singled out radiation oncology for payment cuts that put access to cancer care for Medicare beneficiaries in peril – at a time when cancer incidence rates are rising due to delayed screenings caused by the COVID-19 pandemic. By proposing to cut high-value radiation treatments by as much as 22% and proceeding with more than $160 million in reductions under the Radiation Oncology Model (RO Model), CMS is jeopardizing the ability of the nation’s radiation therapy professionals to continue to provide essential care for their patients now and in the future. Access to life-saving cancer treatments will suffer, and the viability of clinics already reeling from the pandemic will be at considerable risk if these proposals are finalized.

Given this urgent situation, the radiation oncology community calls upon President Joe Biden, a lifelong champion in the fight against cancer, to immediately intervene on the flawed RO model and proposed Medicare Physician Fee Schedule cuts. Likewise, we ask Congress to continue its longstanding support for radiation oncology care by taking action to blunt CMS’ draconian cuts and reform the RO model.

ASTRO remains committed to value-based care and to constructively engaging with CMS on reasonable ways to improve these policies. We are eager to help President Biden achieve his goal of ending cancer as we know it, and we are developing promising approaches to reduce health care disparities in cancer treatment. These difficult policy challenges require investments in our human and technological cancer care infrastructure that would be virtually impossible under the current proposals. Massive cuts such as those proposed by CMS will set us back, not move us forward, and ASTRO will vigorously oppose these threats to radiation oncology and our patients.”

For more information: www.astro.org


Related Content

News | RSNA | By Christine Book

November 27, 2022 — Among dozens of technical exhibit visits, informative discussions, and captivating Plenary Session ...

Time November 27, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — Using a special type of MRI, researchers have uncovered brain changes in patients up to six months ...

Time November 21, 2022
arrow
Videos | ASTRO

Dr. Frank A. Vicini, MD, FACR, FASTRO, FABS, who is a radiation oncologist with GenesisCare, discussed his findings from ...

Time November 09, 2022
arrow
News | Radiation Therapy

November 8, 2022 — Elekta announced that Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform, received FDA ...

Time November 08, 2022
arrow
News | Artificial Intelligence

Nov. 4, 2022 — Guerbet announced an agreement with Merative formalizing the termination of their collaboration initiated ...

Time November 05, 2022
arrow
News | Artificial Intelligence

Nov. 4, 2022 — The U.S. Food and Drug Administration (FDA) is recommending health care providers discuss alternative ...

Time November 05, 2022
arrow
News | Proton Therapy

November 3, 2022 — Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation ...

Time November 03, 2022
arrow
Feature | Lung Imaging | By Christine Book

The pace of new lung cancer screening initiatives, published research and collective efforts of organizations and ...

Time November 03, 2022
arrow
News | Radiation Therapy

November 2, 2022 — ViewRay, Inc. announced the launch of a phase III randomized controlled trial titled "Locally ...

Time November 02, 2022
arrow
Subscribe Now